Chemotherapies and targeted therapies in advanced hepatpcellular carcinoma: From laboratory to clinic

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 3, 2008, Pages 315-322

  Voiculescu, Mihai ^a   Winkler, Robert E ^b   Moscovici, Marius ^c   Neuman, Manuela G ^d  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b Novartis Oncology Global Drug Development   (United States)

^c Pharma Clinical AG Zug   (Switzerland)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alcoholic liver disease; Apoptosis; Cytokines; Fas; Hepatocellular carcinoma; m Tor inhibitor; Primary biliary cirrhosis; Protein kinase C; Tumor necrosis factors; Vascular endothelial growth factor; Viral hepatitis

Indexed keywords

ANTIESTROGEN; BEVACIZUMAB; CYTOCHROME P450 3A; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; HEPATITIS B VIRUS X PROTEIN; INITIATION FACTOR 4E; INTERFERON; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MITOXANTRONE; OCTREOTIDE; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TAMOXIFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ALCOHOL CONSUMPTION; APOPTOSIS; AUTOIMMUNE HEPATITIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CHOLESTASIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG TARGETING; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL DISEASE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; METABOLIC DISORDER; MONOTHERAPY; NONHUMAN; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN DISEASE;

EID: 54349123581     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. World Health Organization. Mortality database. WHO statistical information system. Available at: http://www.who.int/whosis/. Accesed July 2008.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
4. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006; 25: 3848-3856.
5. Parkin DM, Bray F, Ferlay Y, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
6. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5-S16.
7. Voiculescu M. Textbook of Internal Medicine (ed. L. Gherasim). Chapter: Liver tumors. Editura Medicala, Bucuresti, 1999; 977-1009.
8. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 27: 1372-1380.
9. Ries LAG, Harkins D, Krapcho M, et al Eds. SEER Cancer statistics review, 1975-2003, National Cancer Institute Bethesda, MD-2006.
10. Kim W R, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242.
11. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
12. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 1129-1133.
13. Colombo M, de Franchis R, Del Ninno E, et al.: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680.
14. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801.
15. Prates MD, Torres FO. A cancer survey in Lourenco Marques, Portuguese East Africa. J Natl Cancer Inst 1965; 35: 729-757.
16. Bralet MP, Regimbeau JM, Pineau P, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000; 32: 200-204.
17. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994; 17: 71-91.
18. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-438.
19. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106: 1000-1005.
20. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987; 7: 302-306.
21. Munoz N, Bosch X. Epidemiology of hepatocellular carcinoma. In: Neoplasms of the Liver. Okuda K, Ishak KG (Eds), Springer, Tokyo 1989. p.3.
22. Chen CJ, Liang KY, Chang AS, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991; 13: 398-406.
23. Lin TM, Chen CJ, Lu SN, et al. Hepatitis B virus e antigen and primary hepatocellular carcinoma. Anticancer Res 1991; 11: 2063-2065.
24. Lu SN, Lin TM, Chen CJ, et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62: 2051-2055.
25. Tsai JF, Jeng JE, Ho MS, et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996; 73: 1498-1502.
26. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51: 5621-5625.
27. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
28. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
29. Chen CJ, Yang HI, Iloeje U, et al. Models to predict hepatocellular carcinoma in patients with chronic hepatitis B infection: The REVEAL HBV study (abstract). Hepatology 2005; 42 Suppl 1: 714A.
30. Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C- related hepatocellular carcinoma: A prospective study. Ann Intern Med 2007; 146: 649-656.
31. Neuman MG, Sha K, Esguerra R, et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008; 53: 1468-1487.
32. Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases. J Gastrointestin Liver Dis 2008; 17: 165-172.
33. Bruix J, Barters JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-1006.
34. Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006-1008.
35. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331.
36. Bedogni G, Miglioli L, Masutti F, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: The Dionysos Study. Am J Gastroenterol.2008.
37. Fargion S, Fracanzani AL, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20: 1426-1431.
38. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85: 498-502.
39. Neuman M. Cytokines - central factors in alcoholic liver disease. Alcohol Res Health 2003; 27: 307-316,.
40. Cameron RG, Neuman MG, Shear NH, Blendis LM. Multivesicular stellate cells in primary biliary cirrhosis. Hepatology 1997; 26: 819-822.
41. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.
42. Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26: 1138-1142.
43. Chen CJ, Wang LY, Lu SN, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42.
44. Boige V, Taieb J, Hebbar M, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006; 42: 456-459.
45. Villa E, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84: 881-888.
46. Farinati F, Gianni S, Giorgio M, Fiorentini S. Megestrol treatment in patients with hepatocellular carcinoma. Br J Cancer 2001; 85: 1606-1608.
47. Chao Y, Chan WK, Wang SS, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: 277-281.
48. Blaker M, Schmitz M, Gocht A, et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004; 41: 112-118.
49. Cebon J, Findlay M, Hargreaves C, et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006; 95: 853-861.
50. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42: 442-447.
51. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36: 687-691.
52. Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE; HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study. Hepatology 2007; 45: 9-15.
53. Colleoni M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993; 72: 3196-3201.
54. Pohl, J, Zuna, I, Stremmel, W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001; 47:359-361.
55. Porta, C, Moroni, M, Nastasi, G, Arcangeli G. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminay results of a phase II study. Oncology 1995; 52:487-491.
56. Tetef, M, Doroshow, J, Akman, S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 1995; 13:460-463.
57. Boige, V, Raoul, JL, Pignon, JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007; 97:862-867.
58. Cheng, AL, Chuang, SE, Fine, RL, et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998; 55:523-531.
59. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109:917-922.
60. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67.
61. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663.
62. Thomas MB, Chadha R, Iwasaki M, et al. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25: 214s.
63. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
64. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
65. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006; 42: 548-556.
66. Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84: 1377-1383.
67. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108.
68. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003; 3:19.
69. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392-406.
70. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
71. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004; 5: 519-523.
72. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
73. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
74. Frattini M, Balestra D, Suardi S, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004; 10: 4015-4021.
75. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its function and alterations in human cancer. Apoptosis 2004; 9: 667-676.
76. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559.
77. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
78. Huynh H, Chow KP, Soo KC, et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2008.
79. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007; 46: 840-848.
80. Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866-3884.
81. Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplant is not associated with hepatic artery or wound complicationtions. Liver Transpl 2003; 9: 463-468.
82. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007; 13: 764s-769s.
83. Toso C, Meeberg GA, BigamDL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162-1168.
84. Neuman MG. Apoptosis in liver disease. Rom J Gastroenterol 2002; 11: 3-7.
85. Tanaka S, Wands JR. Insulin receptor substrate I overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996; 56: 3391-3394.
86. Lara-Pezzi E, Majano PL, Gómez-Gonzalo C, et al. The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology 1998; 28: 1013-1021.
87. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Bréchot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation efforts of HBx. Oncogene 1999; 18: 4848-4859.
88. Herr I, Schemmer P, Büchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology 2007: 46: 266-274.